Printer Friendly

HARRIER FILES GLYCOSYLATION PATENT APPLICATIONS

 HARRIER FILES GLYCOSYLATION PATENT APPLICATIONS
 LOS ANGELES, Sept. 28 /PRNewswire/ -- Harrier, Inc. (NASDAQ: HARE),


said today that it filed Continuation-in-Part (CIP) patent applications with the U.S. Patent Office covering significant additions to its glycosylation technology directed toward the synthesis of pharmaceuticals. The technology is being developed under a research program sponsored by Harrier at the University of Michigan.
 Glycosylation is a chemical reaction by which a sugar or carbohydrate is attached to an organic molecule, thereby altering the structure and characteristics of the compound of which the molecule is a part. The company had earlier filed patent applications on its glycosylation process technology for the attachment of a simple sugar.
 The recent filings cover the expanded applicability of Harrier's process to more complex sugars and to the successful glycosylation at other chemical sites in a compound's structure previously difficult or impossible to accomplish by standard methods. The most important of these alternative sugars is a naturally-occurring sugar with important biological functions in human metabolism. Subsequent research also disclosed that the attachment could be performed directly on a number of diverse structures in a molecular chain, thereby permitting Harrier's synthesizing process to be employed with greater ease and flexibility than with other known methods.
 Kevin DeVito, Harrier's president, stated: "Many important pharmaceutical agents require glycosylation during synthesis to enhance their efficacy and/or reduce side effects. Our proprietary process represents a promising alternative to a more effective, less costly and less toxic route to this end. Our current efforts are directed to the glycosylation of known, heretofore nonglycosylated drugs, and to the discovery of new drugs with improved pharmacological properties," he said.
 -0- 9/28/92
 /CONTACT: Kevin DeVito, president of Harrier, 310-376-7721/
 (HARE) CO: Harrier, Inc. ST: California IN: MTC SU:


GK-OS -- NY032 -- 3931 09/28/92 11:29 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 28, 1992
Words:301
Previous Article:LANDS' END ANNOUNCES PLANS FOR U.K. PHONE AND DISTRIBUTION CENTER; ORDERS TO BE SHIPPED WITHIN 24 HOURS OF RECEIPT
Next Article:PILLSBURY PROMOTES CHAN AND PIACEK-LLANES TO NEW POSITIONS
Topics:


Related Articles
HARRIER SPONSORS PHARMACEUTICAL RESEARCH PROJECT AT U. OF MICHIGAN; ENTERS SEPARATE AGREEMENT TO FUND BIOCHEMICAL DEVELOPMENT ACTIVITY
SECOM TIES WITH HARRIER FOR JOINT R AND D OF NEW ANTI-CANCER DRUG
HARRIER ESTABLISHES BIOCHEMICAL SUBSIDIARY
ALTEON GRANTED EUROPEAN PATENT COVERING A.G.E. TECHNOLOGY
HARRIER PLANS IND SUBMISSION
ALTEON SIGNS AGREEMENT WITH WASHINGTON UNIVERSITY
Harrier, Inc., Subsidiary Glycosyn Pharmaceuticals Announces Purchase and Agreement to Merge With New Concept Therapeutics, Inc.
Alteon Announces Issuance of Eleven Patents Related to A.G.E. Technology.
Alteon Granted Patent on New Class of A.G.E. Crosslink Breakers; Compounds Have Potential to Reverse Age-Related Diseases.
TKT Announces Issuance of U.S. Patent Covering Iduronate 2-Sulfatase Enzyme For the Treatment of Hunter Syndrome (MPS II).

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters